Evidence map›Paper›PMID 31489190›Full record

ArticleSAGE open medicine2019

Treatment procedures and associated medical costs of methicillin-resistant

Akira Yuasa, Tatsunori Murata, Keiji Imai, Yuji Yamamoto, Yoko Fujimoto

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in SAGE open medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
    Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Akira YuasaMedical Affairs, Pfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0002-3699-7231
Tatsunori MurataCRECON Medical Assessment, Inc., Tokyo, Japan.
Keiji ImaiMedical Affairs, Pfizer Japan Inc., Tokyo, Japan.
Yuji YamamotoMinaCare Co., Ltd, Tokyo, Japan.
Yoko FujimotoMedical Affairs, Pfizer Japan Inc., Tokyo, Japan.
Pfizer (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aimed to determine the patient characteristics, treatment procedures, and medical costs of methicillin-resistant

methodsUsing the MinaCare database of healthcare information covering nearly 3 million individuals, of which 90% were aged 20-59 years, we extracted and analyzed data of patients who were aged ⩾15 years and diagnosed with methicillin-resistant

resultsA total of 684 patients with methicillin-resistant

conclusionAlthough the proportion of patients with methicillin-resistant

Indexed as

Claims databasemedical costmethicillin-resistant Staphylococcus aureusmortality ratereal-world data

Identifiers

PMID31489190
PMCPMC6710669
OpenAlexW2969433801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.